Back to Search Start Over

Cyclooxygenase-2 Is an Obligatory Factor in Methamphetamine-Induced Neurotoxicity

Authors :
David M. Thomas
Donald M. Kuhn
Source :
Journal of Pharmacology and Experimental Therapeutics. 313:870-876
Publication Year :
2005
Publisher :
American Society for Pharmacology & Experimental Therapeutics (ASPET), 2005.

Abstract

Methamphetamine causes persistent damage to dopamine nerve endings of the striatum. The mechanisms underlying its neurotoxicity are not fully understood, but considerable evidence points to oxidative stress as a probable mechanism. A recent microarray analysis of gene expression changes caused by methamphetamine revealed that cyclooxygenase-2 (COX-2) was induced along with its transcription factor CCAAT/enhancer-binding protein (Thomas DM, Francescutti-Verbeem DM, Liu X, and Kuhn DM, 2004). We report presently that methamphetamine increases striatal expression of COX-2 protein. Cyclooxygenase-1 (COX-1) expression was not changed. Mice bearing a null mutation of the gene for COX-2 were resistant to methamphetamine-induced neurotoxicity. COX-1 knockouts, like wild-type mice, showed extensive dopamine nerve terminal damage. Selective inhibitors of COX-1 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl pyrazole (SC-560)], COX-2 [N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398), rofecoxib], or COX-3 (antipyrine) or a nonselective inhibitor of the COX-1/2 isoforms (ketoprofen) did not protect mice from neurotoxicity. Finally, methamphetamine did not change striatal prostaglandin E(2) content. Taken together, these data suggest that COX-2 is an obligatory factor in methamphetamine-induced neurotoxicity. The functional aspect of COX-2 that contributes to drug-induced neurotoxicity does not appear to be its prostaglandin synthetic capacity. Instead, the peroxidase activity associated with COX-2, which can lead to the formation of reactive oxygen species and dopamine quinones, can account for its role.

Details

ISSN :
15210103 and 00223565
Volume :
313
Database :
OpenAIRE
Journal :
Journal of Pharmacology and Experimental Therapeutics
Accession number :
edsair.doi.dedup.....52f2630e91111033f7dc14a743a80c73
Full Text :
https://doi.org/10.1124/jpet.104.080242